View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 26, 2016updated 09 Aug 2019 9:29am

Pfizer completes patient enrolment in bococizumab SPIRE-2 cardiovascular outcome study

Pfizer has completed enrolment in the global SPIRE-2 cardiovascular outcome trial of its investigational agent bococizumab, in high-risk patients without a history of cardiovascular events.

Pfizer has completed enrolment in the global SPIRE-2 cardiovascular outcome trial of its investigational agent bococizumab, in high-risk patients without a history of cardiovascular events.

Bococizumab is a Proprotein Convertase Subtilisin Kexin type 9 inhibitor (PCSK9i) being studied for its potential to lower LDL-C and improve cardiovascular outcomes in high-risk primary and secondary prevention patients.

SPIRE-2 study expects to evaluate the efficacy and safety of bococizumab compared to placebo by reducing the risk of major cardiovascular events among around 10,600 patients at high risk for cardiovascular disease, including those without a prior history of the events and who are also on highly-effective statins or with documented statin intolerance.

The study is one of two cardiovascular outcome trials that are part of the SPIRE Phase lll global clinical development programme, which will evaluate the investigational proprotein convertase subtilisin kexin type 9 inhibitor (PCSK9i) bococizumab in around 32,000 patients with high cholesterol.

"According to a report by World Health Organisation, cardiovascular disease remains the leading cause of death worldwide."

The multicentre, double-blind SPIRE-2 study is expected to be completed by the second half of next year.

The SPIRE-2 study is one of two cardiovascular outcome trials that are part of the SPIRE Phase III global clinical development programme, which will evaluate the investigational PCSK9i bococizumab in approximately 32,000 patients with high cholesterol.

During the SPIRE-2 trial, patients with LDL-C =100 mg/dL or non-HDL-C =130 mg/dL were randomised to receive either bococizumab 150mg or placebo every two weeks, along with highly-effective statins, unless patients had documented statin intolerance.

The main endpoint in SPIRE-2 is timed to the first occurrence of a major cardiovascular event, such as cardiovascular-related death, non-fatal heart attack, non-fatal stroke, and hospitalisation for unstable angina needing urgent revascularisation including heart bypass, angioplasty.

The study is also evaluating other endpoints, including the safety and tolerability of bococizumab.

According to a report by World Health Organisation, cardiovascular disease remains the leading cause of death worldwide.

Various other studies have found that high LDL-C is a known modifiable risk factor for cardiovascular events such as a heart attack and stroke.

However, despite the availability of highly effective lipid-lowering therapies such as statins, many patients remain at high risk for cardiovascular events.

In the US, more than 70% of heart attacks reportedly occur in patients without a previous cardiovascular event.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena